PrEP Injection
PrEP Injection

Yes! PrEP Injection is underway, and you can reach sooner than u think. What makes it even more ambiguous case law that has been forming condemning the seropositive to years in jail simply for not informadoa his new sexual parcero about their HIV status ... and u ask: Telling that? For Candinha tell everyone and ruin my life? I sounded married, and I'm out of this scheme, but if it were single, would take all precautions and minhs not count!

People who use Truvada as pre-exposure prophylaxis (PrEP) and those already infected with HIV may soon be able to say goodbye to their daily pills scheme. SearchPresented late last monthIn 16º Annual Workshop on Clinical Pharmacology of HIV and Hepatitis C Treatment in Washington, DC, shows promise for a monthly PrEP, or even injectable and quarterly, Cabotegravir dose.

"The moment I saw the first poster for The GSK744 the IAS in Washington, DC, in July 2012 conference, I immediately recognized that this was the presentation, it was the presentation OF sofa in the conference," said Jules Levin, executive director the NATAP, who presented the update.

"This would be a major evolution in the treatment of HIV and Prep. Imagine - HIV treatment delivered at one time each three months, of injecting drug and prepare, each face three months in injectable form.

What it is a major development, a breakthrough in science. "

Cabotegravir, is a long term integrase inhibitor. It is a new generation of drugs, different from the currently used Truvada Gilead in use as Prep today, which has been a "star over many years.

Cabotegravir, also known as GSK 444 has not yet been approved by the US Food and Drug Administration. It is being developed jointly by GlaxoSmithKline and ViiV Healthcare.

Used as Prep, the drug is in phase II and III clinical trials among men who have sex with men and transgender as well as women in the Americas and Thailand. It has been proven to be safe and effective in preventing vaginal transmission of HIV in monkeys.

The results from PrEP trials in men are expected later this year and early next year.

Used as an injectable treatment usolongo and lasting in treating people infected with HIV.

It is expected to enter phase III trials Cabotegravir along with another drug, Rilpivarine, early next year.

The news is important because the detractors of PrE largely Michael Weinstein of the AIDS Healthcare Foundation, say those who have HIV likely to be noncompliant. An injectable version, which ensures long-term, delivery health a clear definition.

Preliminary tests have shown efficacy and safety. The drug would be injected in the buttocks.

Used as Prep, Cabotegravir initially can be deployed in oral form to speed up approval.

Levin concluded his presentation last month declaring "substantial progress" in the development and proven efficacy ofCabotegraviras PrEP

david heltsBy: David Heitz

June 14th, 2015



by Claudio de Souza Santoson June 14 2015